S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
Log in
NASDAQ:NUVA

NuVasive Stock Forecast, Price & News

$44.43
-4.84 (-9.82 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$44.13
Now: $44.43
$47.28
50-Day Range
$47.43
MA: $51.50
$56.12
52-Week Range
$28.55
Now: $44.43
$81.91
Volume3.60 million shs
Average Volume902,559 shs
Market Capitalization$2.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
Read More
NuVasive logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Employees2,800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$4.67 per share
Book Value$17.58 per share

Profitability

Net Income$65.23 million

Miscellaneous

Market Cap$2.28 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$44.43
-4.84 (-9.82 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NuVasive (NASDAQ:NUVA) Frequently Asked Questions

How has NuVasive's stock been impacted by Coronavirus?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NUVA stock has decreased by 10.1% and is now trading at $44.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NuVasive?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NuVasive
.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for NuVasive
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its earnings results on Thursday, October, 29th. The medical device company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.31. The medical device company had revenue of $295.30 million for the quarter, compared to analysts' expectations of $257.70 million. NuVasive had a negative net margin of 0.36% and a positive return on equity of 8.33%. NuVasive's revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the business posted $0.59 EPS.
View NuVasive's earnings history
.

What price target have analysts set for NUVA?

17 Wall Street analysts have issued twelve-month price targets for NuVasive's shares. Their forecasts range from $52.00 to $93.00. On average, they expect NuVasive's share price to reach $67.63 in the next year. This suggests a possible upside of 52.2% from the stock's current price.
View analysts' price targets for NuVasive
.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 47, Pay $2.43M)
  • Mr. Matthew W. Link, Pres (Age 45, Pay $1.15M)
  • Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 46, Pay $686.56k)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 50)
  • Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 40)

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.46%), Ziegler Capital Management LLC (0.33%), Envestnet Asset Management Inc. (0.09%), State of New Jersey Common Pension Fund D (0.08%), Comerica Bank (0.06%) and WINTON GROUP Ltd (0.05%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive
.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Dupont Capital Management Corp, New Mexico Educational Retirement Board, New Mexico Educational Retirement Board, Envestnet Asset Management Inc., Comerica Bank, State of Alaska Department of Revenue, and Nisa Investment Advisors LLC. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link, and Paul Mcclintock.
View insider buying and selling activity for NuVasive
.

Which institutional investors are buying NuVasive stock?

NUVA stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Ziegler Capital Management LLC, Pacer Advisors Inc., Keybank National Association OH, Acorn Financial Advisory Services Inc. ADV, XTX Markets LLC, State of New Jersey Common Pension Fund D, and IFP Advisors Inc.
View insider buying and selling activity for NuVasive
.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $44.43.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.28 billion and generates $1.17 billion in revenue each year. The medical device company earns $65.23 million in net income (profit) each year or $2.47 on an earnings per share basis. NuVasive employs 2,800 workers across the globe.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.